Oxford Biomedica PLC Director Dealings / Market Share Purchase (0566A)
24 May 2019 - 3:04AM
UK Regulatory
TIDMOXB
RNS Number : 0566A
Oxford Biomedica PLC
23 May 2019
Director Dealings / Market Share Purchase
Oxford, UK - 23 May 2019: Oxford Biomedica plc ("Oxford
Biomedica" or "the Group") (LSE: OXB), a leading gene and cell
therapy group, today announces that Dr. Lorenzo Tallarigo, Chairman
of the Group, has purchased 388 ordinary shares of 50p each
("Ordinary Shares") in the Company on 23 May 2019 on the London
Stock Exchange at a price of 689.5p per share as set out below
under the market share purchase agreement outlined in the Group's
announcement on 15 December 2015.
Under the market share purchase agreement, one-third of Dr.
Tallarigo's fees as Chairman, after tax, are to be used to purchase
ordinary shares in Oxford Biomedica plc on a monthly basis at the
prevailing market price.
Following this purchase Dr. Tallarigo holds 49,887 ordinary
shares representing 0.07% of the Company.
The below notification, made in accordance with the requirements
of the EU Market Abuse Regulation, gives further detail of the
number of Ordinary Shares purchased.
1. Details of the person discharging material responsibilities/person
closely associated
a. Name Lorenzo Tallarigo
2. Reason for the notification
a. Position/status Chairman
b. Initial notification Initial notification
/amendment
3. Details of the issuer, emission allowance, market
participant, auction platform, auctioneer or auction
monitor
a. Name Oxford Biomedica plc
b. Legal Entity Identifier 213800S1GVQNXQ15K851
4. Details of the transaction(s); section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
a. Description of Oxford Biomedica plc Ordinary Shares
the financial of 50p each
instrument, type GB00BDFBVT43
of instrument
identification
code
b. Nature of the Purchase of ordinary shares
transaction
c. Currency GBP - British Pound
d. Price(s) and volume(s) Price(s) Volume(s)
GBP6.895 388
e. Aggregated information 388
* Aggregated volume GBP6.8946
GBP2,675.10
* Price
* Aggregated total
f. Date of the transaction 2019-05-23
g. Place of the transaction London Stock Exchange, Main Market (XLON)
The issued share capital of the Group is 68,863,354 ordinary 50p
shares.
-Ends-
For further information, please contact:
Oxford Biomedica plc: Tel: +44 (0)1865 783 000
Stuart Paynter, Company Secretary
About Oxford Biomedica
Oxford Biomedica (LSE:OXB) is a leading gene and cell therapy
group focused on developing life changing treatments for serious
diseases. Oxford Biomedica and its subsidiaries (the "Group") have
built a sector leading lentiviral vector delivery platform
(LentiVector(R) ), which the Group leverages to develop in vivo and
ex vivo products both in-house and with partners. The Group has
created a valuable proprietary portfolio of gene and cell therapy
product candidates in the areas of oncology, ophthalmology and CNS
disorders. The Group has also entered into a number of
partnerships, including with Novartis, Sanofi, Axovant Gene
Therapies, Orchard Therapeutics, Boehringer Ingelheim, the UK
Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations,
through which it has long-term economic interests in other
potential gene and cell therapy products. Oxford Biomedica is based
across several locations in Oxfordshire, UK and employs more than
430 people. Further information is available at www.oxb.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHUORBRKAAVUAR
(END) Dow Jones Newswires
May 23, 2019 13:04 ET (17:04 GMT)
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Apr 2024 to May 2024
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From May 2023 to May 2024